Factor IX polypeptide preparations
A pharmaceutical composition with a factor IX polypeptide fused to an FcRn binding partner, combined with specific additives, addresses the short half-life issue in hemophilia B treatment, enabling less frequent dosing and improved bleeding management.
Patent Information
- Application Number
- JP2023147524
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2013-03-15
- Filing Date
- 2023-09-12
- Publication Date
- 2025-09-17
- Estimated Expiration
- 2034-03-14
AI Technical Summary
Current treatments for hemophilia B, caused by factor IX deficiency, suffer from short half-life and require frequent administration, leading to suboptimal patient compliance and effectiveness.
A pharmaceutical composition comprising a factor IX polypeptide fused to an FcRn binding partner (rFIXFBP) combined with sucrose, mannitol, sodium chloride, L-histidine, and polysorbate, designed to provide long-acting factor IX activity, is administered intravenously at specific doses for prophylaxis and treatment of bleeding episodes.
The composition extends the half-life of factor IX, allowing for less frequent administration and improved management of bleeding episodes in hemophilia B patients, enhancing treatment efficacy and patient quality of life.